{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:53:47Z","timestamp":1790704427025,"version":"4.1.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is the second most diagnosed cancer and the fifth leading cause of cancer death among men worldwide. Androgen receptor (AR), as a ligand-activated transcription factor, is important for both prostate development and PCa progression. Understanding the molecular mechanisms of prostate carcinogenesis has led to the development of therapeutic strategies targeting AR. Inhibiting AR is currently the gold standard for hormone therapy. However, eventually resistance to therapy occurs. The activation of AR by supraphysiological androgen levels (SAL) used currently in clinical trials paradoxically also inhibits PCa progression and induces cellular senescence. Interestingly, circadian rhythm controls hormone biosynthesis including androgens. Intriguingly, SNPs in several clock genes have been associated with PCa risk linking increased cancer risk with day-night shifts. Here, we discuss whether the efficacy of hormone therapeutics depends on the biological clock. It emerges that androgens control the expression of clock genes also intersecting with SAL-induced cellular senescence suggesting a complex and understudied network that governs PCa progression. This review highlights the multifaceted roles of AR signaling in PCa, emphasizing its ability to promote cellular senescence by AR-targeted therapy via genomic and non-genomic pathways and crosstalk with the regulation of circadian clock genes. The intricate interplay between circadian rhythm, androgen signaling, and cellular senescence presents a promising yet underexplored research area in PCa and suggests a multilayered regulatory network that could shape PCa progression and treatment outcomes. Unraveling this network may uncover novel chronotherapeutic strategies and provide new insights into disease, prognosis, and therapy options.<\/jats:p>","DOI":"10.1007\/s10555-025-10302-1","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:51:25Z","timestamp":1763628685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The intricate interplay between circadian rhythm, androgen signaling, hormone therapy, and cellular senescence in prostate cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Mehdi","family":"Heidari Horestani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Baniahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"10302_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fonc.2019.00858","volume":"9","author":"Q Feng","year":"2019","unstructured":"Feng, Q., & He, B. (2019). Androgen receptor signaling in the development of castration-resistant prostate cancer. Frontiers in Oncology, 9, 858.","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10302_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer, E. J., Laversanne, M., Sung, H., Soerjomataram, I., Briganti, A., Dahut, W., et al. (2025). Recent patterns and trends in global prostate cancer incidence and mortality: An update. European Urology, 87(3), 302\u2013313.","journal-title":"European Urology"},{"issue":"8","key":"10302_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/1940-6207.CAPR-15-0431","volume":"9","author":"AM De Marzo","year":"2016","unstructured":"De Marzo, A. M., Haffner, M. C., Lotan, T. L., Yegnasubramanian, S., & Nelson, W. G. (2016). Premalignancy in prostate cancer: Rethinking what we know. Cancer Prevention Research (Philadelphia, Pa.), 9(8), 648\u2013656.","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"issue":"1","key":"10302_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.juro.2016.06.080","volume":"197","author":"A Thorstenson","year":"2017","unstructured":"Thorstenson, A., Garmo, H., Adolfsson, J., & Bratt, O. (2017). Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: A nationwide population based study. Journal of Urology, 197(1), 61\u201366. https:\/\/doi.org\/10.1016\/j.juro.2016.06.080","journal-title":"Journal of Urology"},{"issue":"2","key":"10302_CR5","first-page":"62","volume":"6","author":"PP Banerjee","year":"2018","unstructured":"Banerjee, P. P., Banerjee, S., Brown, T. R., & Zirkin, B. R. (2018). Androgen action in prostate function and disease. American Journal of Clinical and Experimental Urology, 6(2), 62.","journal-title":"American Journal of Clinical and Experimental Urology"},{"issue":"1","key":"10302_CR6","first-page":"216","volume":"2","author":"N Kuwahara","year":"2021","unstructured":"Kuwahara, N., Nicholson, K., Isaacs, L., & MacLusky, N. J. (2021). Androgen effects on neural plasticity. Androgens: Clinical Research and Therapeutics, 2(1), 216\u2013230.","journal-title":"Androgens: Clinical Research and Therapeutics"},{"issue":"12","key":"10302_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122780","volume":"12","author":"N-V Mohamad","year":"2024","unstructured":"Mohamad, N.-V., Razali, N.-S.C., & Shamsuddin, N.-A.M. (2024). Dehydroepiandrosterone and bone health: Mechanisms and insights. Biomedicines, 12(12), Article 2780.","journal-title":"Biomedicines"},{"issue":"21","key":"10302_CR8","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.3390\/cancers13215417","volume":"13","author":"A Jacob","year":"2021","unstructured":"Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021). Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers, 13(21), 5417.","journal-title":"Cancers"},{"issue":"1","key":"10302_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/15476286.2022.2084839","volume":"19","author":"E Likos","year":"2022","unstructured":"Likos, E., Bhattarai, A., Weyman, C. M., & Shukla, G. C. (2022). The androgen receptor messenger RNA: What do we know? RNA Biology, 19(1), 819\u2013828.","journal-title":"RNA Biology"},{"issue":"17","key":"10302_CR10","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1158\/0008-5472.CAN-06-1482","volume":"66","author":"S Perner","year":"2006","unstructured":"Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F. H., Mosquera, J.-M., Setlur, S., et al. (2006). TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research, 66(17), 8337\u20138341.","journal-title":"Cancer Research"},{"issue":"3","key":"10302_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","volume":"85","author":"M Corpetti","year":"2024","unstructured":"Corpetti, M., Mueller, C., Beltran, H., de Bono, J., & Theurillat, J.-P. (2024). Prostate-specific membrane antigen\u2013targeted therapies for prostate cancer: Towards improving therapeutic outcomes. European Urology, 85(3), 193\u2013204.","journal-title":"European Urology"},{"issue":"6","key":"10302_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","volume":"52","author":"J Groskopf","year":"2006","unstructured":"Groskopf, J., Aubin, S. M., Deras, I. L., Blase, A., Bodrug, S., Clark, C., et al. (2006). APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clinical Chemistry, 52(6), 1089\u20131095.","journal-title":"Clinical Chemistry"},{"issue":"3","key":"10302_CR13","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015). Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Translational Andrology and Urology, 4(3), 365.","journal-title":"Translational Andrology and Urology"},{"issue":"20","key":"10302_CR14","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.3390\/ijms222011088","volume":"22","author":"T Pungsrinont","year":"2021","unstructured":"Pungsrinont, T., Kallenbach, J., & Baniahmad, A. (2021). Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. International Journal of Molecular Sciences, 22(20), 11088.","journal-title":"International Journal of Molecular Sciences"},{"issue":"13","key":"10302_CR15","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/cancers13133272","volume":"13","author":"LK Jillson","year":"2021","unstructured":"Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021). Androgen receptor signaling in prostate cancer genomic subtypes. Cancers, 13(13), 3272.","journal-title":"Cancers"},{"issue":"3","key":"10302_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/1008-682X.122876","volume":"16","author":"MP Edlind","year":"2014","unstructured":"Edlind, M. P., & Hsieh, A. C. (2014). PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian Journal of Andrology, 16(3), 378\u2013386.","journal-title":"Asian Journal of Andrology"},{"issue":"6315","key":"10302_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1126\/science.aah4965","volume":"354","author":"J Bass","year":"2016","unstructured":"Bass, J., & Lazar, M. A. (2016). Circadian time signatures of fitness and disease. Science, 354(6315), 994\u2013999.","journal-title":"Science"},{"issue":"15","key":"10302_CR18","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1158\/0008-5472.CAN-19-0566","volume":"79","author":"AA Shafi","year":"2019","unstructured":"Shafi, A. A., & Knudsen, K. E. (2019). Cancer and the circadian clock. Cancer Research, 79(15), 3806\u20133814.","journal-title":"Cancer Research"},{"issue":"1","key":"10302_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2022.0474","volume":"20","author":"C Huang","year":"2023","unstructured":"Huang, C., Zhang, C., Cao, Y., Li, J., & Bi, F. (2023). Major roles of the circadian clock in cancer. Cancer Biology & Medicine, 20(1), 1\u201324.","journal-title":"Cancer Biology & Medicine"},{"issue":"7","key":"10302_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1055-9965.EPI-16-1030","volume":"26","author":"MG Wendeu-Foyet","year":"2017","unstructured":"Wendeu-Foyet, M. G., & Menegaux, F. (2017). Circadian disruption and prostate cancer risk: An updated review of epidemiological evidences. Cancer Epidemiology, Biomarkers & Prevention, 26(7), 985\u2013991.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"11","key":"10302_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s10552-016-0815-5","volume":"27","author":"BA Dickerman","year":"2016","unstructured":"Dickerman, B. A., Markt, S. C., Koskenvuo, M., Hublin, C., Pukkala, E., Mucci, L. A., & Kaprio, J. (2016). Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: A 30-year prospective cohort study of Finnish twins. Cancer Causes & Control, 27(11), 1361\u20131370. https:\/\/doi.org\/10.1007\/s10552-016-0815-5","journal-title":"Cancer Causes & Control"},{"issue":"2","key":"10302_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/1055-9965.EPI-14-1274","volume":"25","author":"SC Markt","year":"2016","unstructured":"Markt, S. C., Flynn-Evans, E. E., Valdimarsdottir, U. A., Sigurdardottir, L. G., Tamimi, R. M., Batista, J. L., et al. (2016). Sleep duration and disruption and prostate cancer risk: A 23-year prospective study. Cancer Epidemiology, Biomarkers & Prevention, 25(2), 302\u2013308.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"7","key":"10302_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2645","volume":"7","author":"Y Lee","year":"2021","unstructured":"Lee, Y., Fong, S. Y., Shon, J., Zhang, S. L., Brooks, R., Lahens, N. F., et al. (2021). Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Science Advances, 7(7), Article eabd2645.","journal-title":"Science Advances"},{"issue":"3","key":"10302_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10928-021-09751-2","volume":"48","author":"VS Ayyar","year":"2021","unstructured":"Ayyar, V. S., & Sukumaran, S. (2021). Circadian rhythms: Influence on physiology, pharmacology, and therapeutic interventions. Journal of Pharmacokinetics and Pharmacodynamics, 48(3), 321\u2013338.","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10302_CR25","doi-asserted-by":"publisher","first-page":"1421204","DOI":"10.3389\/fcell.2024.1421204","volume":"12","author":"H Xia","year":"2024","unstructured":"Xia, H., Zhan, Y., Wang, L., & Wang, X. (2024). Exploring the interplay between circadian rhythms and prostate cancer: Insights into androgen receptor signaling and therapeutic opportunities. Frontiers in Cell and Developmental Biology, 12, 1421204.","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"22","key":"10302_CR26","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1101\/gad.1971610","volume":"24","author":"T Kuilman","year":"2010","unstructured":"Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010). The essence of senescence. Genes & Development, 24(22), 2463\u20132479.","journal-title":"Genes & Development"},{"issue":"1","key":"10302_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5483\/BMBRep.2019.52.1.291","volume":"52","author":"SM Kwon","year":"2019","unstructured":"Kwon, S. M., Hong, S. M., Lee, Y.-K., Min, S., & Yoon, G. (2019). Metabolic features and regulation in cell senescence. BMB Reports, 52(1), 5.","journal-title":"BMB Reports"},{"issue":"6","key":"10302_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1083\/jcb.201306073","volume":"203","author":"EC Swanson","year":"2013","unstructured":"Swanson, E. C., Manning, B., Zhang, H., & Lawrence, J. B. (2013). Higher-order unfolding of satellite heterochromatin is a consistent and early event in cell senescence. Journal of Cell Biology, 203(6), 929\u2013942.","journal-title":"Journal of Cell Biology"},{"issue":"12","key":"10302_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/genes8120343","volume":"8","author":"T Nacarelli","year":"2017","unstructured":"Nacarelli, T., Liu, P., & Zhang, R. (2017). Epigenetic basis of cellular senescence and its implications in aging. Genes, 8(12), 343.","journal-title":"Genes"},{"issue":"10","key":"10302_CR30","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1002\/1878-0261.12807","volume":"15","author":"HL Ou","year":"2021","unstructured":"Ou, H. L., Hoffmann, R., Gonz\u00e1lez-L\u00f3pez, C., Doherty, G. J., Korkola, J. E., & Mu\u00f1oz-Esp\u00edn, D. (2021). Cellular senescence in cancer: From mechanisms to detection. Molecular Oncology, 15(10), 2634\u20132671.","journal-title":"Molecular Oncology"},{"key":"10302_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cyto.2019.01.013","volume":"117","author":"S Lopes-Paciencia","year":"2019","unstructured":"Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019). The senescence-associated secretory phenotype and its regulation. Cytokine, 117, 15\u201322.","journal-title":"Cytokine"},{"issue":"7051","key":"10302_CR32","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/436642a","volume":"436","author":"M Collado","year":"2005","unstructured":"Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., et al. (2005). Senescence in premalignant tumours. Nature, 436(7051), 642.","journal-title":"Nature"},{"issue":"1","key":"10302_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41467-023-44514-2","volume":"15","author":"MC Markowski","year":"2024","unstructured":"Markowski, M. C., Taplin, M.-E., Aggarwal, R., Sena, L. A., Wang, H., Qi, H., et al. (2024). Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: The COMBAT phase II trial. Nature Communications, 15(1), 14.","journal-title":"Nature Communications"},{"issue":"12","key":"10302_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.20.02759","volume":"39","author":"SR Denmeade","year":"2021","unstructured":"Denmeade, S. R., Wang, H., Agarwal, N., Smith, D. C., Schweizer, M. T., Stein, M. N., et al. (2021). TRANSFORMER: A randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. Journal of Clinical Oncology, 39(12), 1371\u20131382.","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 8","key":"10302_CR35","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.10.32","volume":"7","author":"JT Isaacs","year":"2019","unstructured":"Isaacs, J. T., Brennen, W. N., & Denmeade, S. R. (2019). Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine, 7(Suppl 8), Article S311. https:\/\/doi.org\/10.21037\/atm.2019.10.32","journal-title":"Annals of Translational Medicine"},{"issue":"5","key":"10302_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.eururo.2020.06.042","volume":"79","author":"MC Markowski","year":"2021","unstructured":"Markowski, M. C., Wang, H., Sullivan, R., Rifkind, I., Sinibaldi, V., Schweizer, M. T., et al. (2021). A multicohort open-label phase II trial of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer (RESTORE): A comparison of post-abiraterone versus post-enzalutamide cohorts. European Urology, 79(5), 692\u2013699.","journal-title":"European Urology"},{"key":"10302_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejca.2020.11.043","volume":"144","author":"LA Sena","year":"2021","unstructured":"Sena, L. A., Wang, H., ScM, S. J. L., Rifkind, I., Ngomba, N., Isaacs, J. T., Lim ScM, S. J., Luo, J., Pratz, C., Sinibaldi, V., Carducci, M. A., Paller, C. J., Eisenberger, M. A., Markowski, M. C., Antonarakis, E. S., & Denmeade, S. R. (2021). Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 144, 302\u2013309. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.043","journal-title":"European Journal of Cancer"},{"key":"10302_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162396","author":"LA Sena","year":"2022","unstructured":"Sena, L. A., Kumar, R., Sanin, D. E., Thompson, E. A., Rosen, D. M., Dalrymple, S. L., et al. (2022). Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI162396","journal-title":"Journal of Clinical Investigation"},{"issue":"269","key":"10302_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010563","volume":"7","author":"MT Schweizer","year":"2015","unstructured":"Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., et al. (2015). Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine, 7(269), Article 269ra2\u2013ra2.","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10302_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-13-214","volume":"13","author":"J Roediger","year":"2014","unstructured":"Roediger, J., Hessenkemper, W., Bartsch, S., Manvelyan, M., Huettner, S. S., Liehr, T., et al. (2014). Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Molecular Cancer, 13(1), 1\u201315.","journal-title":"Molecular Cancer"},{"key":"10302_CR41","doi-asserted-by":"crossref","unstructured":"Roozbahani, G. A., Horestani, M. H., Schindler, K., Kallenbach, J., Baniahmad, A. (2025). Induction of cellular senescence by androgen receptor agonist or antagonist is mediated via two novel common DYRK1A-DREAM and cyclin G2 signaling pathways in castration-resistant prostate cancer. Journal of Advanced Research.","DOI":"10.1016\/j.jare.2025.05.019"},{"issue":"1","key":"10302_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-024-03097-6","volume":"43","author":"M Heidari Horestani","year":"2024","unstructured":"Heidari Horestani, M., Atri Roozbahani, G., & Baniahmad, A. (2024). The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer. Journal of Experimental & Clinical Cancer Research, 43(1), 1\u201319.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"23","key":"10302_CR43","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1038\/s41388-022-02333-7","volume":"41","author":"M Ehsani","year":"2022","unstructured":"Ehsani, M., Bartsch, S., Rasa, S. M. M., Dittmann, J., Pungsrinont, T., Neubert, L., et al. (2022). The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2. Oncogene, 41(23), 3263\u20133277.","journal-title":"Oncogene"},{"key":"10302_CR44","doi-asserted-by":"crossref","unstructured":"Saatcioglu, F. (2011). Androgen action: Methods and protocols: Springer.","DOI":"10.1007\/978-1-61779-243-4"},{"issue":"14","key":"10302_CR45","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1073\/pnas.0401123101","volume":"101","author":"PL Shaffer","year":"2004","unstructured":"Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., & Gewirth, D. T. (2004). Structural basis of androgen receptor binding to selective androgen response elements. Proceedings of the National Academy of Sciences, 101(14), 4758\u20134763.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10302_CR46","first-page":"148","volume":"2","author":"C Cai","year":"2013","unstructured":"Cai, C., Yuan, X., & Balk, S. P. (2013). Androgen receptor epigenetics. Translational Andrology and Urology, 2(3), 148.","journal-title":"Translational Andrology and Urology"},{"issue":"3","key":"10302_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","volume":"7","author":"RE Vickman","year":"2020","unstructured":"Vickman, R. E., Franco, O. E., Moline, D. C., Vander Griend, D. J., Thumbikat, P., & Hayward, S. W. (2020). The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian Journal of Urology, 7(3), 191\u2013202.","journal-title":"Asian Journal of Urology"},{"issue":"11","key":"10302_CR48","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/2159-8290.CD-19-1028","volume":"9","author":"JW Russo","year":"2019","unstructured":"Russo, J. W., Nouri, M., & Balk, S. P. (2019). Androgen receptor interaction with mediator complex is enhanced in castration-resistant prostate cancer by CDK7 phosphorylation of MED1. Cancer Discovery, 9(11), 1490\u20131492.","journal-title":"Cancer Discovery"},{"key":"10302_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00936","author":"Y Hou","year":"2019","unstructured":"Hou, Y., Zhang, R., & Sun, X. (2019). Enhancer LncRNAs influence chromatin interactions in different ways. Frontiers in Genetics. https:\/\/doi.org\/10.3389\/fgene.2019.00936","journal-title":"Frontiers in Genetics"},{"key":"10302_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00377","author":"PR Arnold","year":"2020","unstructured":"Arnold, P. R., Wells, A. D., & Li, X. C. (2020). Diversity and emerging roles of enhancer RNA in regulation of gene expression and cell fate. Frontiers in Cell and Developmental Biology. https:\/\/doi.org\/10.3389\/fcell.2019.00377","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1","key":"10302_CR51","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey, R. A., & Grossmann, M. (2016). Androgen receptor structure, function and biology: From bench to bedside. The Clinical Biochemist Reviews, 37(1), 3\u201315.","journal-title":"The Clinical Biochemist Reviews"},{"key":"10302_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/er.2016-1067","volume":"38","author":"RS Swerdloff","year":"2017","unstructured":"Swerdloff, R. S., Dudley, R. E., Page, S., Wang, C., & Salameh, W. A. (2017). Dihydrotestosterone: Biochemistry, physiology, and clinical implications of elevated blood levels. Endocrine Reviews, 38, 220\u2013254.","journal-title":"Endocrine Reviews"},{"key":"10302_CR53","doi-asserted-by":"crossref","unstructured":"Snaterse, G., van Dessel, L. F., van Riet, J., Taylor, A. E., Vlugt-Daane Mvd, Hamberg, P., et al. (2021). 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration. JCI Insight, 6.","DOI":"10.1172\/jci.insight.148507"},{"key":"10302_CR54","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/jc.2017-01525","volume":"103","author":"J Rege","year":"2018","unstructured":"Rege, J., Turcu, A. F., Kasa-Vubu, J., Ler\u00e1rio, A. M., Auchus, G. C., Auchus, R. J., et al. (2018). 11-ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche. The Journal of Clinical Endocrinology & Metabolism, 103, 4589\u20134598.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"15","key":"10302_CR55","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1016\/j.biortech.2008.01.039","volume":"99","author":"A Malaviya","year":"2008","unstructured":"Malaviya, A., & Gomes, J. (2008). Androstenedione production by biotransformation of phytosterols. Bioresource Technology, 99(15), 6725\u20136737.","journal-title":"Bioresource Technology"},{"issue":"20","key":"10302_CR56","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.3390\/molecules26206210","volume":"26","author":"MT Badawy","year":"2021","unstructured":"Badawy, M. T., Sobeh, M., Xiao, J., & Farag, M. A. (2021). Androstenedione (a natural steroid and a drug supplement): A comprehensive review of its consumption, metabolism, health effects, and toxicity with sex differences. Molecules, 26(20), 6210.","journal-title":"Molecules"},{"issue":"7_Part_1","key":"10302_CR57","first-page":"1163","volume":"25","author":"C Huggins","year":"1965","unstructured":"Huggins, C. (1965). Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference. Cancer Research, 25(7_Part_1), 1163\u20131167.","journal-title":"Cancer Research"},{"issue":"7","key":"10302_CR58","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022). Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease, 13(7), 632.","journal-title":"Cell Death & Disease"},{"key":"10302_CR59","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00716","author":"W Xiang","year":"2022","unstructured":"Xiang, W., & Wang, S. (2022). Therapeutic strategies to target the Androgen Receptor. Journal of Medicinal Chemistry. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00716","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10302_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0002-9343(92)90741-S","volume":"92","author":"J-L Gomez","year":"1992","unstructured":"Gomez, J.-L., Dupont, A., Cusan, L., Tremblay, M., Suburu, R., Lemay, M., et al. (1992). Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. The American Journal of Medicine, 92(5), 465\u2013470.","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"10302_CR61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ajur.2020.03.002","volume":"7","author":"R Narayanan","year":"2020","unstructured":"Narayanan, R. (2020). Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. Asian Journal of Urology, 7(3), 271\u2013283.","journal-title":"Asian Journal of Urology"},{"issue":"29","key":"10302_CR62","doi-asserted-by":"publisher","first-page":"26321","DOI":"10.1074\/jbc.M203310200","volume":"277","author":"D Masiello","year":"2002","unstructured":"Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. Journal of Biological Chemistry, 277(29), 26321\u201326326.","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10302_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SC Williams","year":"2023","unstructured":"Williams, S. C., Mazibuko, N., O\u2019Daly, O., Zurth, C., Patrick, F., Kappeler, C., et al. (2023). Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: A randomized crossover trial. Targeted Oncology, 18(3), 403\u2013413.","journal-title":"Targeted Oncology"},{"key":"10302_CR64","doi-asserted-by":"crossref","unstructured":"Abbasi, A., Movahedpour, A., Amiri, A., Samare-Najaf, M., & Mostafavipour, Z. (2020). Darolutamide as a second-generation Androgen receptor inhibitor in the treatment of prostate cancer. Current Molecular Medicine.","DOI":"10.2174\/1566524020666200903120344"},{"key":"10302_CR65","unstructured":"Medicine NLo. EPI-7386 in combination with enzalutamide compared with enzalutamide alone in subjects with MCRPC 2025 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05075577."},{"issue":"4","key":"10302_CR66","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","volume":"24","author":"LB Snyder","year":"2025","unstructured":"Snyder, L. B., Neklesa, T. K., Willard, R. R., Gordon, D. A., Pizzano, J., Vitale, N., et al. (2025). Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader. Molecular Cancer Therapeutics, 24(4), 511\u2013522.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"10302_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","volume":"19","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios, P. J., Puca, L., & Beltran, H. (2017). Emerging variants of castration-resistant prostate cancer. Current Oncology Reports, 19(5), 32.","journal-title":"Current Oncology Reports"},{"key":"10302_CR68","doi-asserted-by":"crossref","unstructured":"Yang, Z., Ping, Y.-Q., Wang, M.-W., Zhang, C., Zhou, S.-H., Xi, Y.-T., et al. (2025). Identification, structure, and agonist design of an androgen membrane receptor. Cell, 188(6):1589\u2013604. e24.","DOI":"10.1016\/j.cell.2025.01.006"},{"key":"10302_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52032-y","author":"R Safi","year":"2024","unstructured":"Safi, R., Wardell, S. E., Watkinson, P., Qin, X., Lee, M. R., Park, S., et al. (2024). Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. Nature Communications. https:\/\/doi.org\/10.1038\/s41467-024-52032-y","journal-title":"Nature Communications"},{"issue":"4","key":"10302_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0898-6568(02)00115-8","volume":"15","author":"C Rochette-Egly","year":"2003","unstructured":"Rochette-Egly, C. (2003). Nuclear receptors: Integration of multiple signalling pathways through phosphorylation. Cellular Signalling, 15(4), 355\u2013366.","journal-title":"Cellular Signalling"},{"issue":"6","key":"10302_CR71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.biocel.2009.11.013","volume":"42","author":"NC Bennett","year":"2010","unstructured":"Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010). Molecular cell biology of androgen receptor signalling. The International Journal of Biochemistry & Cell Biology, 42(6), 813\u2013827.","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"12","key":"10302_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119357","volume":"1869","author":"V Dahiya","year":"2022","unstructured":"Dahiya, V., & Bagchi, G. (2022). Non-canonical androgen signaling pathways and implications in prostate cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 1869(12), Article 119357.","journal-title":"Biochimica Et Biophysica Acta - Molecular Cell Research"},{"key":"10302_CR73","doi-asserted-by":"crossref","unstructured":"Singh, J. P., Dagar, M., Dagar, G., Kumar, S., Rawal, S., & Sharma, R. D., et al. (2019). Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells. PLoS ONE, 15.","DOI":"10.1101\/851667"},{"key":"10302_CR74","doi-asserted-by":"publisher","first-page":"19900","DOI":"10.1074\/jbc.271.33.19900","volume":"271","author":"LV Nazareth","year":"1996","unstructured":"Nazareth, L. V., & Weigel, N. L. (1996). Activation of the human androgen receptor through a protein kinase A signaling pathway*. Journal of Biological Chemistry, 271, 19900\u201319907.","journal-title":"Journal of Biological Chemistry"},{"key":"10302_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrc3037","volume":"11","author":"MC Hollander","year":"2011","unstructured":"Hollander, M. C., Blumenthal, G., & Dennis, P. A. (2011). PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer, 11, 289\u2013301.","journal-title":"Nature Reviews Cancer"},{"key":"10302_CR76","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1124\/mol.118.115014","volume":"95","author":"R Ye","year":"2019","unstructured":"Ye, R., Pi, M., Nooh, M. M., Bahout, S. W., & Quarles, L. D. (2019). Human GPRC6A mediates testosterone-induced mitogen-activated protein kinases and mTORC1 signaling in prostate cancer cells. Molecular Pharmacology, 95, 563\u2013572.","journal-title":"Molecular Pharmacology"},{"key":"10302_CR77","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/sj.onc.1203032","volume":"18","author":"H Peterziel","year":"1999","unstructured":"Peterziel, H., Mink, S., Schonert, A., Becker, M., Klocker, H., & Cato, A. C. B. (1999). Rapid signalling by androgen receptor in prostate cancer cells. Oncogene, 18, 6322\u20136329.","journal-title":"Oncogene"},{"issue":"44","key":"10302_CR78","doi-asserted-by":"publisher","first-page":"42992","DOI":"10.1074\/jbc.M306295200","volume":"278","author":"M Sun","year":"2003","unstructured":"Sun, M., Yang, L., Feldman, R. I., Sun, X.-m, Bhalla, K. N., Jove, R., et al. (2003). Activation of phosphatidylinositol 3-kinase\/Akt pathway by androgen through interaction of p85\u03b1, androgen receptor, and Src. Journal of Biological Chemistry, 278(44), 42992\u201343000.","journal-title":"Journal of Biological Chemistry"},{"issue":"7","key":"10302_CR79","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41388-021-02125-5","volume":"41","author":"K Mirzakhani","year":"2022","unstructured":"Mirzakhani, K., Kallenbach, J., Rasa, S. M. M., Ribaudo, F., Ungelenk, M., Ehsani, M., et al. (2022). Correction to: The androgen receptor\u2014lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. Oncogene, 41(7), 1071\u20131077.","journal-title":"Oncogene"},{"key":"10302_CR80","doi-asserted-by":"publisher","first-page":"29584","DOI":"10.1074\/jbc.M703310200","volume":"282","author":"B Cinar","year":"2007","unstructured":"Cinar, B., Mukhopadhyay, N. K., Meng, G., & Freeman, M. R. (2007). Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains*. Journal of Biological Chemistry, 282, 29584\u201329593.","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"10302_CR81","first-page":"2132","volume":"60","author":"T Chen","year":"2000","unstructured":"Chen, T., Wang, L., & Farrar, W. L. (2000). Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Research, 60(8), 2132\u20132135.","journal-title":"Cancer Research"},{"issue":"4","key":"10302_CR82","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1389450116666151019094724","volume":"17","author":"E Sikora","year":"2016","unstructured":"Sikora, E., Mosieniak, G., & \u015aliwi\u0144ska, M. A. (2016). Morphological and functional characteristic of senescent cancer cells. Current Drug Targets, 17(4), 377\u2013387.","journal-title":"Current Drug Targets"},{"key":"10302_CR83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","volume":"25","author":"L Hayflick","year":"1961","unstructured":"Hayflick, L., & Moorhead, P. S. (1961). The serial cultivation of human diploid cell strains. Experimental Cell Research, 25, 585\u2013621.","journal-title":"Experimental Cell Research"},{"key":"10302_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvab115","author":"R Ahmed","year":"2021","unstructured":"Ahmed, R., Reza, H. M., Shinohara, K., & Nakahata, Y. (2021). Cellular senescence and its impact on the circadian clock. The Journal of Biochemistry. https:\/\/doi.org\/10.1093\/jb\/mvab115","journal-title":"The Journal of Biochemistry"},{"issue":"1","key":"10302_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-022-00941-0","volume":"12","author":"J Kallenbach","year":"2022","unstructured":"Kallenbach, J., Atri Roozbahani, G., Heidari Horestani, M., & Baniahmad, A. (2022). Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. Cell & Bioscience, 12(1), 1\u201317.","journal-title":"Cell & Bioscience"},{"key":"10302_CR86","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1101\/gad.223834.113","volume":"27","author":"PP Shah","year":"2013","unstructured":"Shah, P. P., Donahue, G., Otte, G. L., Capell, B. C., Nelson, D. M., Cao, K., et al. (2013). Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes & Development, 27, 1787\u20131799.","journal-title":"Genes & Development"},{"key":"10302_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-022-00197-8","author":"N Ohtani","year":"2022","unstructured":"Ohtani, N. (2022). The roles and mechanisms of senescence-associated secretory phenotype (SASP): Can it be controlled by senolysis? Inflammation and Regeneration. https:\/\/doi.org\/10.1186\/s41232-022-00197-8","journal-title":"Inflammation and Regeneration"},{"key":"10302_CR88","doi-asserted-by":"publisher","first-page":"784","DOI":"10.4161\/cc.6.7.4079","volume":"6","author":"R Zhang","year":"2007","unstructured":"Zhang, R., & Adams, P. D. (2007). Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle, 6, 784\u2013789.","journal-title":"Cell Cycle"},{"key":"10302_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063355","author":"T Oizumi","year":"2024","unstructured":"Oizumi, T., Suzuki, T., Kobayashi, J., & Nakamura, A. J. (2024). Senescence-associated heterochromatin foci suppress \u03b3-H2AX focus formation induced by radiation exposure. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25063355","journal-title":"International Journal of Molecular Sciences"},{"key":"10302_CR90","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153581","author":"R Maeda","year":"2022","unstructured":"Maeda, R., & Tachibana, M. (2022). HP1 maintains protein stability of H3K9 methyltransferases and demethylases. EMBO Reports. https:\/\/doi.org\/10.15252\/embr.202153581","journal-title":"EMBO Reports"},{"key":"10302_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01798-1","author":"H Liu","year":"2020","unstructured":"Liu, H., Huang, B., Xue, S., U, K. P., Tsang, L. L., Zhang, X., et al. (2020). Functional crosstalk between mTORC1\/p70S6K pathway and heterochromatin organization in stress-induced senescence of MSCs. Stem Cell Research & Therapy. https:\/\/doi.org\/10.1186\/s13287-020-01798-1","journal-title":"Stem Cell Research & Therapy"},{"issue":"1","key":"10302_CR92","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.devcel.2004.10.019","volume":"8","author":"R Zhang","year":"2005","unstructured":"Zhang, R., Poustovoitov, M. V., Ye, X.-f, Santos, H., Chen, W., Daganzo, S. M., et al. (2005). Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Developmental Cell, 8(1), 19\u201330.","journal-title":"Developmental Cell"},{"key":"10302_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102206","volume":"83","author":"I Olan","year":"2023","unstructured":"Olan, I., Handa, T., & Narita, M. (2023). Beyond SAHF: An integrative view of chromatin compartmentalization during senescence. Current Opinion in Cell Biology, 83, Article 102206. https:\/\/doi.org\/10.1016\/j.ceb.2023.102206","journal-title":"Current Opinion in Cell Biology"},{"key":"10302_CR94","first-page":"866","volume":"203","author":"B Short","year":"2013","unstructured":"Short, B. (2013). Senescent cells have a case of the SADS. Journal of Cell Biology, 203, 866.","journal-title":"Journal of Cell Biology"},{"key":"10302_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae085","author":"D Yeo","year":"2024","unstructured":"Yeo, D., Zars Fisher, E. L., Khosla, S., Farr, J. N., & Westendorf, J. J. (2024). Hdac3-deficiency increases senescence-associated distention of satellite DNA and telomere-associated foci in osteoprogenitor cells. Journal of Bone and Mineral Research. https:\/\/doi.org\/10.1093\/jbmr\/zjae085","journal-title":"Journal of Bone and Mineral Research"},{"key":"10302_CR96","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","volume":"18","author":"W Huang","year":"2022","unstructured":"Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022). Cellular senescence: The good, the bad and the unknown. Nature Reviews Nephrology, 18, 611\u2013627.","journal-title":"Nature Reviews Nephrology"},{"key":"10302_CR97","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1101\/gad.343129.120","volume":"34","author":"J Birch","year":"2020","unstructured":"Birch, J., & Gil, J. (2020). Senescence and the SASP: Many therapeutic avenues. Genes & Development, 34, 1565\u20131576.","journal-title":"Genes & Development"},{"key":"10302_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109441","author":"F Jochems","year":"2021","unstructured":"Jochems, F., Thijssen, B., De Conti, G., Jansen, R. A., Pogacar, Z., Groot, K., et al. (2021). The cancer senescopedia: A delineation of cancer cell senescence. Cell Reports. https:\/\/doi.org\/10.1016\/j.celrep.2021.109441","journal-title":"Cell Reports"},{"issue":"2","key":"10302_CR99","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2015.11.011","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley, C. D., Velarde, M. C., Lecot, P., Liu, S., Sarnoski, E. A., Freund, A., et al. (2016). Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metabolism, 23(2), 303\u2013314.","journal-title":"Cell Metabolism"},{"issue":"8","key":"10302_CR100","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/cells14080608","volume":"14","author":"S Alqahtani","year":"2025","unstructured":"Alqahtani, S., Alqahtani, T., Venkatesan, K., Sivadasan, D., Ahmed, R., Sirag, N., et al. (2025). SASP modulation for cellular rejuvenation and tissue homeostasis: Therapeutic strategies and molecular insights. Cells, 14(8), 608.","journal-title":"Cells"},{"key":"10302_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102309","author":"Y Valieva","year":"2022","unstructured":"Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A. V., & Igrunkova, A. (2022). Senescence-associated \u03b2-galactosidase detection in pathology. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics12102309","journal-title":"Diagnostics"},{"key":"10302_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202404885","author":"AG Baker","year":"2024","unstructured":"Baker, A. G., Hartono, M., Ou, H.-L., Popov, A. B., Brown, E. L., Joseph, J., et al. (2024). An indocyanine green\u2010based nanoprobe for in vivo detection of cellular senescence. Angewandte Chemie (International Ed in English). https:\/\/doi.org\/10.1002\/anie.202404885","journal-title":"Angewandte Chemie (International Ed in English)"},{"issue":"16","key":"10302_CR103","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.3390\/cancers13164025","volume":"13","author":"S Bartsch","year":"2021","unstructured":"Bartsch, S., Mirzakhani, K., Neubert, L., Stenzel, A., Ehsani, M., Esmaeili, M., et al. (2021). Antithetic hTERT regulation by androgens in prostate cancer cells: HTERT inhibition is mediated by the ING1 and ING2 tumor suppressors. Cancers, 13(16), 4025.","journal-title":"Cancers"},{"issue":"14","key":"10302_CR104","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1111\/febs.12258","volume":"280","author":"D Ding","year":"2013","unstructured":"Ding, D., Zhou, J., Wang, M., & Cong, Y. S. (2013). Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. The FEBS Journal, 280(14), 3205\u20133211.","journal-title":"The FEBS Journal"},{"issue":"3","key":"10302_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jmcb\/mjw007","volume":"8","author":"M Esmaeili","year":"2016","unstructured":"Esmaeili, M., Jennek, S., Ludwig, S., Klitzsch, A., Kraft, F., Melle, C., et al. (2016). The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells. Journal of Molecular Cell Biology, 8(3), 207\u2013220.","journal-title":"Journal of Molecular Cell Biology"},{"key":"10302_CR106","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00109-016-1440-1","volume":"94","author":"M Esmaeili","year":"2016","unstructured":"Esmaeili, M., Pungsrinont, T., Schaefer, A., & Baniahmad, A. (2016). A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling. Journal of Molecular Medicine, 94, 1167\u20131179.","journal-title":"Journal of Molecular Medicine"},{"key":"10302_CR107","doi-asserted-by":"publisher","unstructured":"Mirzakhani, K., Heidari Horestani, M., Kallenbach, J., Atri Roozbahani, G., & Baniahmad, A. (2024). The novel direct AR target gene annexin A2 mediates androgen-induced cellular senescence in prostate cancer cells. Biochemical Genetics(6). https:\/\/doi.org\/10.1007\/s10528-024-10953-9","DOI":"10.1007\/s10528-024-10953-9"},{"issue":"1","key":"10302_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-024-03233-2","volume":"43","author":"J Kallenbach","year":"2024","unstructured":"Kallenbach, J., Rasa, M., Heidari Horestani, M., Atri Roozbahani, G., Schindler, K., & Baniahmad, A. (2024). The oncogenic lncRNA MIR503HG suppresses cellular senescence counteracting supraphysiological androgen treatment in prostate cancer. Journal of Experimental & Clinical Cancer Research, 43(1), 1\u201321.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"5","key":"10302_CR109","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1097\/JS9.0000000000002334","volume":"111","author":"M Taheri","year":"2025","unstructured":"Taheri, M., Schindler, K., & Baniahmad, A. (2025). The lncRNAs PART1 and ADAMTS9-AS2 act in an antithetic manner on AR signaling and induction of cellular senescence in prostate cancer cells. International Journal of Surgery (London, England), 111(5), 3646\u20133664. https:\/\/doi.org\/10.1097\/JS9.0000000000002334","journal-title":"International Journal of Surgery (London, England)"},{"key":"10302_CR110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.18632\/aging.100871","volume":"8","author":"A Bernadotte","year":"2016","unstructured":"Bernadotte, A., Mikhelson, V. M., & Spivak, I. (2016). Markers of cellular senescence. Telomere shortening as a marker of cellular senescence. Aging (Albany NY), 8, 3\u201311.","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10302_CR111","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/cancers17050791","volume":"17","author":"M Heidari Horestani","year":"2025","unstructured":"Heidari Horestani, M., Atri Roozbahani, G., & Baniahmad, A. (2025). H2AJ is a direct androgen receptor target gene that regulates androgen-induced cellular senescence and inhibits mesenchymal markers in prostate cancer cells. Cancers, 17(5), 791.","journal-title":"Cancers"},{"issue":"1","key":"10302_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-024-01970-7","volume":"22","author":"M Heidari Horestani","year":"2024","unstructured":"Heidari Horestani, M., Schindler, K., & Baniahmad, A. (2024). Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence. Cell Communication and Signaling, 22(1), 1\u201320.","journal-title":"Cell Communication and Signaling"},{"issue":"8b","key":"10302_CR113","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/j.1582-4934.2008.00426.x","volume":"13","author":"M Papaioannou","year":"2009","unstructured":"Papaioannou, M., Schleich, S., Prade, I., Degen, S., Roell, D., Schubert, U., et al. (2009). The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. Journal of Cellular and Molecular Medicine, 13(8b), 2210\u20132223.","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"11","key":"10302_CR114","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1210\/me.2014-1170","volume":"28","author":"W Hessenkemper","year":"2014","unstructured":"Hessenkemper, W., Roediger, J., Bartsch, S., Houtsmuller, A. B., van Royen, M. E., Petersen, I., et al. (2014). A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Molecular Endocrinology, 28(11), 1831\u20131840.","journal-title":"Molecular Endocrinology"},{"key":"10302_CR115","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jsbmb.2018.12.005","volume":"188","author":"D Roell","year":"2019","unstructured":"Roell, D., R\u00f6sler, T. W., Hessenkemper, W., Kraft, F., Hauschild, M., Bartsch, S., et al. (2019). Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists. The Journal of Steroid Biochemistry and Molecular Biology, 188, 59\u201370.","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10302_CR116","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K., Shore, N. D., Tammela, T. L. J., Ulys, A., Vjaters, E., Polyakov, S. L., et al. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. The New England Journal of Medicine, 380, 1235\u20131246.","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10302_CR117","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12672-020-00391-5","volume":"11","author":"S Gupta","year":"2020","unstructured":"Gupta, S., Pungsrinont, T., \u017denata, O., Neubert, L., Vrzal, R., & Baniahmad, A. (2020). Interleukin-23 represses the level of cell senescence induced by the androgen receptor antagonists enzalutamide and darolutamide in castration-resistant prostate cancer cells. Hormones and Cancer, 11(3), 182\u2013190. https:\/\/doi.org\/10.1007\/s12672-020-00391-5","journal-title":"Hormones and Cancer"},{"issue":"10","key":"10302_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13948","volume":"22","author":"H Power","year":"2023","unstructured":"Power, H., Valtchev, P., Dehghani, F., & Schindeler, A. (2023). Strategies for senolytic drug discovery. Aging Cell, 22(10), Article e13948. https:\/\/doi.org\/10.1111\/acel.13948","journal-title":"Aging Cell"},{"issue":"1","key":"10302_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41514-024-00138-4","volume":"10","author":"V Lelarge","year":"2024","unstructured":"Lelarge, V., Capelle, R., Oger, F., Mathieu, T., & Le Calv\u00e9, B. (2024). Senolytics: From pharmacological inhibitors to immunotherapies, a promising future for patients\u2019 treatment. NPJ Aging, 10(1), Article 12.","journal-title":"NPJ Aging"},{"issue":"2","key":"10302_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13767","volume":"22","author":"MT Islam","year":"2023","unstructured":"Islam, M. T., Tuday, E., Allen, S., Kim, J., Trott, D. W., Holland, W. L., Donato, A. J., & Lesniewski, L. A. (2023). Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging Cell, 22(2), Article e13767. https:\/\/doi.org\/10.1111\/acel.13767","journal-title":"Aging Cell"},{"issue":"7","key":"10302_CR121","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/stmcls\/sxad036","volume":"41","author":"M Mullen","year":"2023","unstructured":"Mullen, M., Nelson, A. L., Goff, A., Billings, J., Kloser, H., Huard, C., et al. (2023). Fisetin attenuates cellular senescence accumulation during culture expansion of human adipose-derived stem cells. Stem Cells, 41(7), 698\u2013710.","journal-title":"Stem Cells"},{"key":"10302_CR122","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fcell.2020.00354","volume":"8","author":"AK Sharma","year":"2020","unstructured":"Sharma, A. K., Roberts, R. L., Benson, R. D., Jr., Pierce, J. L., Yu, K., Hamrick, M. W., et al. (2020). The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice. Frontiers in Cell and Developmental Biology, 8, 354.","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10302_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2023.111888","volume":"217","author":"AN Rad","year":"2024","unstructured":"Rad, A. N., & Grillari, J. (2024). Current senolytics: Mode of action, efficacy and limitations, and their future. Mechanisms of Ageing and Development, 217, Article 111888. https:\/\/doi.org\/10.1016\/j.mad.2023.111888","journal-title":"Mechanisms of Ageing and Development"},{"issue":"11","key":"10302_CR124","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13979","volume":"22","author":"AF Chin","year":"2023","unstructured":"Chin, A. F., Han, J., Clement, C. C., Choi, Y., Zhang, H., Browne, M., Jeon, O. H., & Elisseeff, J. H. (2023). Senolytic treatment reduces oxidative protein stress in an aging male murine model of post\u2010traumatic osteoarthritis. Aging Cell, 22(11), Article e13979. https:\/\/doi.org\/10.1111\/acel.13979","journal-title":"Aging Cell"},{"issue":"5","key":"10302_CR125","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0896-6273(00)80627-3","volume":"21","author":"AM Sangoram","year":"1998","unstructured":"Sangoram, A. M., Saez, L., Antoch, M. P., Gekakis, N., Staknis, D., Whiteley, A., et al. (1998). Mammalian circadian autoregulatory loop: A timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron, 21(5), 1101\u20131113.","journal-title":"Neuron"},{"issue":"5440","key":"10302_CR126","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.286.5440.768","volume":"286","author":"EA Griffin Jr.","year":"1999","unstructured":"Griffin, E. A., Jr., Staknis, D., & Weitz, C. J. (1999). Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science, 286(5440), 768\u2013771.","journal-title":"Science"},{"key":"10302_CR127","doi-asserted-by":"crossref","unstructured":"Cox, K. H., & Takahashi, J. S. (2018). Circadian clock genes and the transcriptional architecture of the clock mechanism. Journal of Molecular Endocrinology.","DOI":"10.1530\/endoabs.59.PL4"},{"key":"10302_CR128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148278","volume":"131","author":"D Guan","year":"2021","unstructured":"Guan, D., & Lazar, M. A. (2021). Interconnections between circadian clocks and metabolism. The Journal of Clinical Investigation, 131, Article 15.","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"10302_CR129","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1073\/pnas.68.9.2112","volume":"68","author":"RJ Konopka","year":"1971","unstructured":"Konopka, R. J., & Benzer, S. (1971). Clock mutants of Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America, 68(9), 2112\u20132116. https:\/\/doi.org\/10.1073\/pnas.68.9.2112","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10302_CR130","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0092-8674(00)80245-7","volume":"89","author":"DP King","year":"1997","unstructured":"King, D. P., Zhao, Y., Sangoram, A. M., Wilsbacher, L. D., Tanaka, M., Antoch, M. P., et al. (1997). Positional cloning of the mouse circadian clock gene. Cell, 89, 641\u2013653.","journal-title":"Cell"},{"issue":"5369","key":"10302_CR131","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1126\/science.280.5369.1564","volume":"280","author":"N Gekakis","year":"1998","unstructured":"Gekakis, N., Staknis, D., Nguyen, H., Davis, F. C., Wilsbacher, L. D., King, D. P., et al. (1998). Role of the CLOCK protein in the mammalian circadian mechanism. Science, 280(5369), 1564\u20131569.","journal-title":"Science"},{"issue":"11","key":"10302_CR132","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1073\/pnas.95.11.6097","volume":"95","author":"Y Miyamoto","year":"1998","unstructured":"Miyamoto, Y., & Sancar, A. (1998). Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. Proceedings of the National Academy of Sciences of the United States of America, 95(11), 6097\u20136102. https:\/\/doi.org\/10.1073\/pnas.95.11.6097","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10302_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0704-0","author":"F Rijo-Ferreira","year":"2019","unstructured":"Rijo-Ferreira, F., & Takahashi, J. S. (2019). Genomics of circadian rhythms in health and disease. Genome Medicine. https:\/\/doi.org\/10.1186\/s13073-019-0704-0","journal-title":"Genome Medicine"},{"issue":"1","key":"10302_CR134","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41420-024-01960-1","volume":"10","author":"Y Zeng","year":"2024","unstructured":"Zeng, Y., Guo, Z., Wu, M., Chen, F., & Chen, L. (2024). Circadian rhythm regulates the function of immune cells and participates in the development of tumors. Cell Death Discovery, 10(1), 199.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"10302_CR135","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-neuro-060909-153128","volume":"35","author":"JA Mohawk","year":"2012","unstructured":"Mohawk, J. A., Green, C. B., & Takahashi, J. S. (2012). Central and peripheral circadian clocks in mammals. Annual Review of Neuroscience, 35(1), 445\u2013462.","journal-title":"Annual Review of Neuroscience"},{"issue":"1","key":"10302_CR136","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.genom.5.061903.175925","volume":"5","author":"PL Lowrey","year":"2004","unstructured":"Lowrey, P. L., & Takahashi, J. S. (2004). Mammalian circadian biology: Elucidating genome-wide levels of temporal organization. Annual Review of Genomics and Human Genetics, 5(1), 407\u2013441. https:\/\/doi.org\/10.1146\/annurev.genom.5.061903.175925","journal-title":"Annual Review of Genomics and Human Genetics"},{"key":"10302_CR137","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0092-8674(02)00825-5","volume":"110","author":"N Preitner","year":"2002","unstructured":"Preitner, N., Damiola, F., Lopez-Molina, L., Zakany, J., Duboule, D., Albrecht, U., et al. (2002). The orphan nuclear receptor REV-ERB\u03b1 controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell, 110, 251\u2013260.","journal-title":"Cell"},{"key":"10302_CR138","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.cell.2013.01.055","volume":"152","author":"S-H Yoo","year":"2013","unstructured":"Yoo, S.-H., Mohawk, J. A., Siepka, S. M., Shan, Y., Huh, S. K., Hong, H., et al. (2013). Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell, 152, 1091\u20131105.","journal-title":"Cell"},{"key":"10302_CR139","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nn1884","volume":"10","author":"JP DeBruyne","year":"2007","unstructured":"DeBruyne, J. P., Weaver, D. R., & Reppert, S. M. (2007). CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nature Neuroscience, 10, 543\u2013545.","journal-title":"Nature Neuroscience"},{"issue":"6909","key":"10302_CR140","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nature01123","volume":"419","author":"S Honma","year":"2002","unstructured":"Honma, S., Kawamoto, T., Takagi, Y., Fujimoto, K., Sato, F., Noshiro, M., et al. (2002). Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature, 419(6909), 841\u2013844.","journal-title":"Nature"},{"issue":"22","key":"10302_CR141","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1111\/j.1432-1033.2004.04379.x","volume":"271","author":"F Sato","year":"2004","unstructured":"Sato, F., Kawamoto, T., Fujimoto, K., Noshiro, M., Honda, K. K., Honma, S., et al. (2004). Functional analysis of the basic helix-loop-helix transcription factor DEC1 in circadian regulation: Interaction with BMAL1. European Journal of Biochemistry, 271(22), 4409\u20134419.","journal-title":"European Journal of Biochemistry"},{"issue":"1","key":"10302_CR142","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2003.11.099","volume":"313","author":"T Kawamoto","year":"2004","unstructured":"Kawamoto, T., Noshiro, M., Sato, F., Maemura, K., Takeda, N., Nagai, R., et al. (2004). A novel autofeedback loop of Dec1 transcription involved in circadian rhythm regulation. Biochemical and Biophysical Research Communications, 313(1), 117\u2013124.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10302_CR143","doi-asserted-by":"publisher","unstructured":"Fortin, B. M., Mahieu, A. L., Fellows, R. C., Kang, Y., Lewis, A. N., Ead, A. S., et al. (2025). The diverse roles of the circadian clock in cancer. Nature Cancer(5). https:\/\/doi.org\/10.1038\/s43018-025-00981-8","DOI":"10.1038\/s43018-025-00981-8"},{"issue":"6524","key":"10302_CR144","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738","volume":"371","author":"A Sancar","year":"2021","unstructured":"Sancar, A., & Van Gelder, R. N. (2021). Clocks, cancer, and chronochemotherapy. Science, 371(6524), Article eabb0738.","journal-title":"Science"},{"issue":"4","key":"10302_CR145","volume":"16","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y., Zheng, Y., Dai, R., & Gu, X. (2024). Crosstalk between circadian rhythm dysregulation and tumorigenesis, tumor metabolism and tumor immune response. Aging and Disease, 16(4), Article 2073.","journal-title":"Aging and Disease"},{"key":"10302_CR146","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fendo.2019.00104","volume":"10","author":"S Morales-Santana","year":"2019","unstructured":"Morales-Santana, S., Morell, S., Leon, J., Carazo-Gallego, A., Jimenez-Lopez, J. C., & Morell, M. (2019). An overview of the polymorphisms of circadian genes associated with endocrine cancer. Frontiers in Endocrinology, 10, 104.","journal-title":"Frontiers in Endocrinology"},{"issue":"24","key":"10302_CR147","doi-asserted-by":"publisher","first-page":"9315","DOI":"10.1158\/0008-5472.CAN-09-0648","volume":"69","author":"Y Zhu","year":"2009","unstructured":"Zhu, Y., Stevens, R. G., Hoffman, A. E., Fitzgerald, L. M., Kwon, E. M., Ostrander, E. A., et al. (2009). Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study. Cancer Research, 69(24), 9315\u20139322.","journal-title":"Cancer Research"},{"issue":"1","key":"10302_CR148","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12916-018-1010-1","volume":"16","author":"S Mocellin","year":"2018","unstructured":"Mocellin, S., Tropea, S., Benna, C., & Rossi, C. R. (2018). Circadian pathway genetic variation and cancer risk: Evidence from genome-wide association studies. BMC Medicine, 16(1), 20.","journal-title":"BMC Medicine"},{"key":"10302_CR149","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/1055-9965.EPI-14-1274","volume":"25","author":"SC Markt","year":"2015","unstructured":"Markt, S. C., Flynn-Evans, E. E., Valdimarsd\u00f3ttir, U. A., Sigurdardottir, L. G., Tamimi, R. M., Batista, J. L., et al. (2015). Sleep duration and disruption and prostate cancer risk: A 23-year prospective study. Cancer Epidemiology, Biomarkers & Prevention, 25, 302\u2013308.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"9","key":"10302_CR150","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/1055-9965.EPI-11-0236","volume":"20","author":"DW Lin","year":"2011","unstructured":"Lin, D. W., FitzGerald, L. M., Fu, R., Kwon, E. M., Zheng, S. L., Kolb, S., et al. (2011). Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiology, Biomarkers & Prevention, 20(9), 1928\u20131936.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"4","key":"10302_CR151","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.pcan.4501024","volume":"11","author":"L Chu","year":"2008","unstructured":"Chu, L., Zhu, Y., Yu, K., Zheng, T., Yu, H., Zhang, Y., et al. (2008). Variants in circadian genes and prostate cancer risk: A population-based study in China. Prostate Cancer and Prostatic Diseases, 11(4), 342\u2013348.","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"1","key":"10302_CR152","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41467-020-20513-5","volume":"12","author":"AA Shafi","year":"2021","unstructured":"Shafi, A. A., McNair, C. M., McCann, J. J., Alshalalfa, M., Shostak, A., Severson, T. M., et al. (2021). The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications, 12(1), 401.","journal-title":"Nature Communications"},{"issue":"17","key":"10302_CR153","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204288","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu, J., Tan, Z., Yang, S., Song, X., & Li, W. (2022). A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma. Aging (Albany NY), 14(17), Article 7170. https:\/\/doi.org\/10.18632\/aging.204288","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"10302_CR154","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.tips.2018.07.003","volume":"39","author":"G Sulli","year":"2018","unstructured":"Sulli, G., Manoogian, E. N. C., Taub, P. R., & Panda, S. (2018). Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases. Trends in Pharmacological Sciences, 39(9), 812\u2013827.","journal-title":"Trends in Pharmacological Sciences"},{"issue":"11","key":"10302_CR155","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1210\/me.2012-1071","volume":"26","author":"L Mao","year":"2012","unstructured":"Mao, L., Dauchy, R. T., Blask, D. E., Slakey, L. M., Xiang, S., Yuan, L., et al. (2012). Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3\u03b2. Molecular Endocrinology, 26(11), 1808\u20131820.","journal-title":"Molecular Endocrinology"},{"issue":"4","key":"10302_CR156","doi-asserted-by":"publisher","first-page":"269","DOI":"10.30802\/AALAS-CM-17-000107","volume":"68","author":"RT Dauchy","year":"2018","unstructured":"Dauchy, R. T., Wren-Dail, M. A., Dupepe, L. M., Hill, S. M., Xiang, S., Anbalagan, M., et al. (2018). Effect of daytime blue-enriched LED light on the nighttime circadian melatonin inhibition of hepatoma 7288CTC Warburg effect and progression. Comparative Medicine, 68(4), 269\u2013279.","journal-title":"Comparative Medicine"},{"key":"10302_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18412-w","author":"L Lundell","year":"2020","unstructured":"Lundell, L., Parr, E. B., Devlin, B. L., Ingerslev, L. R., Alt\u0131nta\u015f, A., Sato, S., et al. (2020). Time-restricted feeding alters lipid and amino acid metabolite rhythmicity without perturbing clock gene expression. Nature Communications. https:\/\/doi.org\/10.1038\/s41467-020-18412-w","journal-title":"Nature Communications"},{"key":"10302_CR158","doi-asserted-by":"crossref","unstructured":"Alidadi, M., Banach, M., Guest, P. C., Bo, S., Jamialahmadi, T., & Sahebkar, A. (2020). The effect of caloric restriction and fasting on cancer. Seminars in Cancer Biology.","DOI":"10.1016\/j.semcancer.2020.09.010"},{"key":"10302_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.03.015","author":"RFN Ribeiro","year":"2021","unstructured":"Ribeiro, R. F. N., Cavadas, C., & Manuel C Silva, M. (2021). Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.015","journal-title":"Drug Discovery Today"},{"issue":"3","key":"10302_CR160","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.bmc.2017.12.020","volume":"26","author":"A Monastyrskyi","year":"2017","unstructured":"Monastyrskyi, A., Nilchan, N., Quereda, V., Noguchi, Y., Ruiz, C. H., Grant, W., et al. (2017). Development of dual casein kinase 1\u03b4\/1\u03b5 (CK1\u03b4\/\u03b5) inhibitors for treatment of breast cancer. Bioorganic & Medicinal Chemistry, 26(3), 590\u2013602.","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10302_CR161","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.4070","volume":"22","author":"J Wang","year":"2016","unstructured":"Wang, J., Zou, J. X., Xue, X.-q, Cai, D., Zhang, Y., Duan, Z., et al. (2016). ROR-\u03b3 drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nature Medicine, 22, 488\u2013496.","journal-title":"Nature Medicine"},{"issue":"8","key":"10302_CR162","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli, G., Lam, M. T. Y., & Panda, S. (2019). Interplay between circadian clock and cancer: New frontiers for cancer treatment. Trends in Cancer, 5(8), 475\u2013494.","journal-title":"Trends in Cancer"},{"issue":"4","key":"10302_CR163","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.1990.8.4.705","volume":"8","author":"FA L\u00e9vi","year":"1990","unstructured":"L\u00e9vi, F. A., Benavides, M., Chevelle, C., Le Saunier, F., Bailleul, F., Misset, J. L., et al. (1990). Chemotherapy of advanced ovarian cancer with 4\u2019-O-tetrahydropyranyl doxorubicin and cisplatin: A randomized phase II trial with an evaluation of circadian timing and dose-intensity. Journal of Clinical Oncology, 8(4), 705\u2013714.","journal-title":"Journal of Clinical Oncology"},{"key":"10302_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083548","author":"T Lei","year":"2025","unstructured":"Lei, T., Yang, Y., & Yang, W.-X. (2025). Luteinizing hormone regulates testosterone production, Leydig cell proliferation, differentiation, and circadian rhythm during spermatogenesis. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms26083548","journal-title":"International Journal of Molecular Sciences"},{"key":"10302_CR165","doi-asserted-by":"publisher","DOI":"10.4103\/aja20258","author":"G Ning","year":"2025","unstructured":"Ning, G., Li, B., Wu, H., Shi, R.-B., Peng, A.-J., Wang, H.-Y., et al. (2025). Regulation of testosterone synthesis by circadian clock genes and its research progress in male diseases. Asian Journal of Andrology. https:\/\/doi.org\/10.4103\/aja20258","journal-title":"Asian Journal of Andrology"},{"key":"10302_CR166","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2012.11.008","volume":"1491","author":"MJ Duncan","year":"2013","unstructured":"Duncan, M. J., Prochot, J., Cook, D. H., Smith, J. T., & Franklin, K. M. (2013). Influence of aging on Bmal1 and Per2 expression in extra-SCN oscillators in hamster brain. Brain Research, 1491, 44\u201353.","journal-title":"Brain Research"},{"key":"10302_CR167","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.cell.2015.04.002","volume":"161","author":"JO Lipton","year":"2015","unstructured":"Lipton, J. O., Yuan, E. D., Boyle, L. M., Ebrahimi-Fakhari, D., Kwiatkowski, E., Nathan, A., et al. (2015). The circadian protein BMAL1 regulates translation in response to S6K1-mediated phosphorylation. Cell, 161, 1138\u20131151.","journal-title":"Cell"},{"key":"10302_CR168","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2014.06.050","volume":"158","author":"S Masri","year":"2014","unstructured":"Masri, S., Rigor, P., Cervantes, M., Ceglia, N., Sebasti\u00e1n, C., Xiao, C., et al. (2014). Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. Cell, 158, 659\u2013672.","journal-title":"Cell"},{"key":"10302_CR169","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nature06394","volume":"450","author":"J Hirayama","year":"2007","unstructured":"Hirayama, J., Sahar, S., Grimaldi, B., Tamaru, T., Takamatsu, K., Nakahata, Y., et al. (2007). CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature, 450, 1086\u20131090.","journal-title":"Nature"},{"key":"10302_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.647589","author":"A Ashimori","year":"2021","unstructured":"Ashimori, A., Nakahata, Y., Sato, T., Fukamizu, Y., Matsui, T., Yoshitane, H., et al. (2021). Attenuated SIRT1 activity leads to PER2 cytoplasmic localization and dampens the amplitude of Bmal1 promoter-driven circadian oscillation. Frontiers in Neuroscience. https:\/\/doi.org\/10.3389\/fnins.2021.647589","journal-title":"Frontiers in Neuroscience"},{"key":"10302_CR171","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cell.2010.08.016","volume":"142","author":"G Asher","year":"2010","unstructured":"Asher, G., Reinke, H., Altmeyer, M., Gutierrez-Arcelus, M., Hottiger, M. O., & Schibler, U. (2010). Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding. Cell, 142, 943\u2013953.","journal-title":"Cell"},{"issue":"2","key":"10302_CR172","doi-asserted-by":"publisher","DOI":"10.1093\/lifemedi\/lnae006","volume":"3","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Xu, X., Chen, Z., Chen, L., Jiang, Y., & Mao, Z. (2024). Circadian factors CLOCK and BMAL1 promote nonhomologous end joining and antagonize cellular senescence. Life Medicine, 3(2), Article lnae006.","journal-title":"Life Medicine"},{"key":"10302_CR173","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3892\/or.2020.7914","volume":"45","author":"M Jia","year":"2020","unstructured":"Jia, M., Su, B., Mo, L., Qiu, W.-s, Ying, J., Lin, P., et al. (2020). Circadian clock protein CRY1 prevents paclitaxel-induced senescence of bladder cancer cells by promoting p53 degradation. Oncology Reports, 45, 1033\u20131043.","journal-title":"Oncology Reports"},{"key":"10302_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041862","author":"Q Xu","year":"2012","unstructured":"Xu, Q., Ma, P.-q, Hu, C., Chen, L., Xue, L., Wang, Z., et al. (2012). Overexpression of the DEC1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0041862","journal-title":"PLoS ONE"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10302-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:04:26Z","timestamp":1763633066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10302-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":174,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10302"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10302-1","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}